<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005860</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067890</org_study_id>
    <secondary_id>MSKCC-99100</secondary_id>
    <secondary_id>NCI-T99-0107</secondary_id>
    <nct_id>NCT00005860</nct_id>
  </id_info>
  <brief_title>Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum</brief_title>
  <official_title>A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of oxaliplatin with or without floxuridine
      and leucovorin in treating patients who have metastatic cancer of the peritoneum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of intraperitoneal oxaliplatin with or without
           intraperitoneal floxuridine and leucovorin calcium in patients with metastatic cancer
           confined to the peritoneal cavity.

        -  Determine dose limiting and nondose limiting toxicities and pharmacokinetics of these
           treatment regimens in this patient population.

      OUTLINE: This is a dose escalation study of oxaliplatin.

      Patients receive intraperitoneal (IP) oxaliplatin over 1 hour on day 1 every 2 weeks for 2
      courses.

      Beginning at course 3, patients receive oxaliplatin with floxuridine and leucovorin calcium
      IP on day 1 and floxuridine and leucovorin calcium IP alone on days 2 and 3. Treatment
      repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
      Patients with complete surgical resection of disease receive a total of 6 courses of
      combination chemotherapy.

      Cohorts of 3-6 patients receive escalating doses of oxaliplatin until the maximum tolerated
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
      of 6 patients experience dose limiting toxicity.

      PROJECTED ACCRUAL: A total of 3-40 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>floxuridine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed metastatic or unresectable cancer largely
             confined to the peritoneal cavity

               -  Fully resected and/or electrocauterized metastatic disease involving the
                  peritoneum (stage IV, no residual disease) allowed

          -  No known brain metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin normal

          -  SGOT/SGPT no greater than 2.5 times upper limit of normal

        Renal:

          -  Creatinine normal OR

          -  Creatinine clearance at least 60 mL/min

        Cardiovascular:

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

        Other:

          -  No history of allergy to platinum compounds or antiemetics that would preclude study

          -  No other uncontrolled illness (e.g., active infection)

          -  No evidence of neuropathy

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or
             nitrosoureas) and recovered

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy and recovered

        Surgery:

          -  See Disease Characteristics

        Other:

          -  No other concurrent investigational agents

          -  No concurrent antiretroviral therapy (HAART)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard B. Saltz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>April 1, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2004</study_first_posted>
  <last_update_submitted>April 23, 2011</last_update_submitted>
  <last_update_submitted_qc>April 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2011</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>regional gastrointestinal carcinoid tumor</keyword>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>gastrinoma</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>insulinoma</keyword>
  <keyword>recurrent islet cell carcinoma</keyword>
  <keyword>WDHA syndrome</keyword>
  <keyword>somatostatinoma</keyword>
  <keyword>pancreatic polypeptide tumor</keyword>
  <keyword>glucagonoma</keyword>
  <keyword>regional pheochromocytoma</keyword>
  <keyword>metastatic pheochromocytoma</keyword>
  <keyword>recurrent pheochromocytoma</keyword>
  <keyword>extragonadal germ cell tumor</keyword>
  <keyword>liver metastases</keyword>
  <keyword>malignant ascites</keyword>
  <keyword>newly diagnosed carcinoma of unknown primary</keyword>
  <keyword>carcinoma of the appendix</keyword>
  <keyword>pseudomyxoma peritonei</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <keyword>recurrent carcinoma of unknown primary</keyword>
  <keyword>gastrointestinal stromal tumor</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

